Hypoglycemia
Inform patients that PRANDIN can cause hypoglycemia and instruct patients and their caregivers on self-management procedures including glucose monitoring and management of hypoglycemia. Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended [see Warnings and Precautions (5.1)].
Administration
Instruct patients to take PRANDIN within 30 minutes before meals. Instruct patients to skip their dose of PRANDIN when a meal is skipped. [see Dosage and Administration (2)].
Drug Interactions
Discuss potential drug interactions with patients and inform them of potential drug-drug interactions with PRANDIN. [see Drug Interactions (7)].
PRANDIN® is a registered trademark of Novo Nordisk A/S.
© 2009-2017 Novo Nordisk
Manufactured for:
Novo Nordisk A/S
DK-2880 Bagsvaerd, Denmark
For information contact:
Novo Nordisk Inc.
800 Scudders Mill Road
Plainsboro, NJ 08536
1-800-727-6500
www.novonordisk-us.com